Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

INTRODUCTION: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xu Steven, Moreau, Philippe, Usmani, Saad Z., Lonial, Sagar, Jakubowiak, Andrzej, Oriol, Albert, Krishnan, Amrita, Bladé, Joan, Luo, Man, Sun, Yu-Nien, Zhou, Honghui, Nnane, Ivo, Deraedt, William, Qi, Ming, Ukropec, Jon, Clemens, Pamela L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140755/
https://www.ncbi.nlm.nih.gov/pubmed/32078124
http://dx.doi.org/10.1007/s12325-020-01247-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140755/
https://www.ncbi.nlm.nih.gov/pubmed/32078124
http://dx.doi.org/10.1007/s12325-020-01247-8

Ejemplares similares